| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |